A review of the current understanding and clinical utility of miRNAs in esophageal cancer

Seminars in Cancer Biology

Volumn 23, Issue 6 PB, 2013, Pages 512-521

  Sakai, Naomi S ^a   Samia Aly, Emma ^a   Barbera, Mariagnese ^b   Fitzgerald, Rebecca C ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

Barrett's esophagus; Biomarkers; Diagnosis; MicroRNA; Oesophageal cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CISPLATIN; ENDORIBONUCLEASE OF RNASE III FAMILY; FLUOROURACIL; MICRORNA; MICRORNA 126; MICRORNA 133A; MICRORNA 133B; MICRORNA 143; MICRORNA 145; MICRORNA 21; MICRORNA 25; MICRORNA 27B; MICRORNA 99A; NUCLEAR PROTEIN; PASHA PROTEIN; RIBONUCLEASE; RIBONUCLEASE 3; UNCLASSIFIED DRUG;

BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE COURSE; DOWN REGULATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GENE EXPRESSION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA SYNTHESIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UPREGULATION;

5-FLUOROURACIL; 5-FU; ASCIN HOMOLOG 1, ACTIN BUNDLING PROTEIN; B CELL LYMPHOMA 2; BARRETT'S ESOPHAGUS; BCL-2; BE; BIOMARKERS; CD47; CDH1; CLUSTER OF DIFFERENTIATION 47; DGCR8; DIAGNOSIS; DICER1; E-CADHERIN; EAC; ENDORIBONUCLEASE OF RNASE III FAMILY; ESCC; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; F BOX/WD REPEAT CONTAINING PROTEIN 7; FBXW7; FSCN1; HGD; HIGH GRADE DYSPLASIA; IGF1R; INFLAMMATORY RISK SCORE; INSULIN LIKE GROWTH FACTOR RECEPTOR 1; IRS; LACTATE DEHYDROGENASE B; LARGE TUMOR SUPPRESSOR, HOMOLOG 2; LATS2; LDHB; LGD; LNM; LOW GRADE DYSPLASIA; LYMPH NODE METASTASIS; MDR1; MICRORNA; MICRORNA [RIBONUCLEIC ACID]; MIRNA IN SITU HYBRIDIZATION; MIRNA/MIR; MISH; MULTI DRUG RESISTANCE 1; NE; NORMAL EPITHELIUM; OESOPHAGEAL CANCER; P27; P53; PASHA PROTEIN; PPP2R1B; PROGNOSIS; PROTEIN 27; PROTEIN 53; PROTEIN PHOSPHATASE 2 REGULATORY SUBUNIT BETA ISOFORM; QRT-PCR; QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RAP1A; RAP1B; RAS RELATED PROTEIN 1A; RAS RELATED PROTEIN 1B; RIBONUCLEASE 3 ENZYME GENE; RIBONUCLEIC ACID; RNA; RNASEN;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84887607910     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.08.005     Document Type: Review

References (72)

1. GLOBOCAN database 2008, [globocan.iarc.fr].
2. Holmes R.S., Vaughan T.L. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007, 17(January (1)):2-9. [Review].
3. Brown L.M., Devesa S.S., Chow W.H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008, 100(August (16)):1184-1187.
4. Bollschweiler E., Wolfgarten E., Gutschow C., Hölscher A.H. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001, 92(August (3)):549-555.
5. Lagergren J., Bergström R., Lindgren A., Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340(March (11)):825-831.
6. Whiteman D.C., Sadeghi S., Pandeya N., Smithers B.M., Gotley D.C., Bain C.J., et al. Australian Cancer Study. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the esophagus. Gut 2008, 57(February (2)):173-180.
7. Desai T.K., Krishnan K., Samala N., Singh J., Cluley J., Perla S., et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagusesophagus: a meta-analysis. Gut 2011, 61(November (7)):970-976.
8. Kamangar F., Malekzadeh R., Dawsey S.M., Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med 2007, 10(January (1)):70-82. [Review].
9. Anderson L.A., Watson R.G., Murphy S.J., Johnston B.T., Comber H., Mc Guigan J., et al. Risk factors for Barrett's oesophagusesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007, 13(March (10)):1585-1594.
10. Vaughan T.L., Davis S., Kristal A., Thomas D.B. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995, 4(March (2)):85-92.
11. Cancer research UK statistics []. http://info.cancerresearchuk.org/cancerstats/.
12. Barbour A.P., Jones M., Brown I., Gotley D.C., Martin I., Thomas J., et al. Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol 2010, 17(September (9)):2494-2502.
13. Pennathur A., Farkas A., Krasinskas A.M., Ferson P.F., Gooding W.E., Gibson M.K., et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg 2009, 87(April (4)):1048-1054.
14. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(November (11)):857-866. [Review].
15. Harfe B.D. MicroRNAs in vertebrate development. Curr Opin Genet Dev 2005, 15:410-415.
16. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302(February (1)):1-12. [Review].
17. miRBase []. http://www.mirbase.org/.
18. Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50(April (4)):298-301. [Erratum in: Methods, 2010 November; 52 (3): 268].
19. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105(July (30)):10513-10518.
20. Ali S., Almhanna K., Chen W., Philip P.A., Sarkar F.H. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res 2010, 3(September (1)):28-47.
21. Sarver A.L. Toward understanding the informatics and statistical aspects of micro-RNA profiling. J Cardiovasc Transl Res 2010, 3(June (3)):204-211.
22. Guo Y., Chen Z., Zhang L., Zhou F., Shi S., Feng X., et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008, 68(January (1)):26-33.
23. Feber A., Xi L., Luketich J.D., Pennathur A., Landreneau R.J., Wu M., et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008, 135(February (2)):255-260.
24. Yang H., Gu J., Wang K.K., Zhang W., Xing J., Chen Z., et al. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009, 15(September (18)):5744-5752.
25. Luo S. MicroRNA expression analysis using the illumina microRNA-Seq platform. Methods Mol Biol 2012, 822:183-188.
26. Soares A.R., Pereira P.M., Santos M.A. Next-generation sequencing of miRNAs with Roche 454 GS-FLX technology: steps for a successful application. Methods Mol Biol 2012, 822:189-204.
27. Kano M., Seki N., Kikkawa N., Fujimura L., Hoshino I., Akutsu Y., et al. miR-145, miR-133a and miR-133b: tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010, 127(March (12)):2804-2814.
28. Ichimi T., Enokida H., Okuno Y., Kunimoto R., Chiyomaru T., Kawamoto K., et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009, 125(July (2)):345-352.
29. Ogawa R., Ishiguro H., Kuwabara Y., Kimura M., Mitsui A., Katada T., et al. Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol 2009, 42(June (2)):102-109.
30. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., et al. A microRNA component of the p53 tumor suppressor network. Nature 2007, 447(June (7148)):1130-1134.
31. Lee K.H., Goan Y.G., Hsiao M., Lee C.H., Jian S.H., Lin J.T., et al. MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Exp Cell Res 2009, 315(September (15)):2529-2538.
32. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
33. Zhu W., Qin W., Atasoy U., Sauter E.R. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2009, 2:89.
34. Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010, 102:1174-1179.
35. Kurashige J., Kamohara H., Watanabe M., Tanaka Y., Kinoshita K., Saito S., et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol 2012, 106(August (2)):188-192.
36. Komatsu S., Ichikawa D., Takeshita H., Tsujiura M., Morimura R., Nagata H., et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011, 105(June (1)):104-111.
37. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (Commentary) 2001, 93(July (14)):1054-1061.
38. Chen Z.L., Zhao X.H., Wang J.W., Li B.Z., Wang Z., Sun J., et al. microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem 2011, 286(March (12)):10725-10734.
39. Akagi I., Miyashita M., Ishibashi O., Mishima T., Kikuchi K., Makino H., et al. Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Dis Esophagus 2011, 24(September (7)):523-530.
40. Hummel R., Hussey D.J., Michael M.Z., Haier J., Bruewer M., Senninger N., et al. MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. Ann Surg Oncol 2011, 18(January (1)):253-260.
41. Mathé E.A., Nguyen G.H., Bowman E.D., Zhao Y., Budhu A., Schetter A.J., et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009, 15(October (19)):6192-6200.
42. Zhao Y., Schetter A.J., Yang G.B., Nguyen G., Mathé E.A., Li P., et al. microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer 2012, 132(November (12)):2901-2909.
43. Hamano R., Miyata H., Yamasaki M., Kurokawa Y., Hara J., Moon J.H., et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 2011, 17(May (9)):3029-3038.
44. Li J., Li X., Li Y., Yang H., Wang L., Qin Y., et al. Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS ONE 2013, 8(1):e53582.
45. Hu Y., Correa A.M., Hoque A., Guan B., Ye F., Huang J., et al. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 2011, 128(January (1)):132-143.
46. Nguyen G.H., Schetter A.J., Chou D.B., Bowman E.D., Zhao R., Hawkes J.E., et al. Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res 2010, 16(December (23)):5824-5834.
47. Sugito N., Ishiguro H., Kuwabara Y., Kimura M., Mitsui A., Kurehara H., et al. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res 2006, 12(December (24)):7322-7328.
48. Pennathur A., Gibson M.K., Jobe B.A., Luketich J.D. Oesophageal carcinoma. Lancet 2013, 381(February (9864)):400-412. 10.1016/S0140-6736(12)60643-6.
49. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(July (1)):11-20.
50. Hong L., Han Y., Zhang H., Li M., Gong T., Sun L., et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010, 251(June (6)):1056-1063.
51. Hummel R., Watson D.I., Smith C., Kist J., Michael M.Z., Haier J., et al. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011, 15(March (3)):429-438.
52. Magrelli A., Azzalin G., Salvatore M., Viganotti M., Tosto F., Colombo T., et al. Altered microRNA expression patterns in hepatoblastoma patients. Transl Oncol 2009, 2(August (3)):157-163.
53. Cai E.H., Gao Y.X., Wei Z.Z., Chen W.Y., Yu P., Li K. Serum miR-21 expression in human esophageal squamous cell carcinomas. Asian Pac J Cancer Prev 2012, 13(4):1563-1567.
54. Zhang T., Wang Q., Zhao D., Cui Y., Cao B., Guo L., et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond) 2011, 121(November (10)):437-447.
55. van Soest E.M., Dieleman J.P., Siersema P.D., Sturkenboom M.C., Kuipers E.J. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005, 54(August (8)):1062-1066.
56. Kan T., Sato F., Ito T., Matsumura N., David S., Cheng Y., et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 2009, 136(May (5)):1689-1700.
57. Leidner R.S., Ravi L., Leahy P., Chen Y., Bednarchik B., Streppel M., et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 2012, 51(May (5)):473-479.
58. Smith C.M., Watson D.I., Leong M.P., Mayne G.C., Michael M.Z., Wijnhoven B.P., et al. miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World J Gastroenterol 2011, 17(February (8)):1036-1044.
59. Fassan M., Volinia S., Palatini J., Pizzi M., Baffa R., De Bernard M., et al. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer 2011, 129(October (7)):1661-1670.
60. Kong K.L., Kwong D.L., Chan T.H., Law S.Y., Chen L., Li Y., et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012, 61(January (1)):33-42.
61. Isozaki Y., Hoshino I., Nohata N., Kinoshita T., Akutsu Y., Hanari N., et al. Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma. Int J Oncol 2012, 41(September (3)):985-994.
62. Suzuki S., Yokobori T., Tanaka N., Sakai M., Sano A., Inose T., et al. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep 2012, 28(August (2)):465-472.
63. Xu X., Chen Z., Zhao X., Wang J., Ding D., Wang Z., et al. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 2012, 421(May (4)):640-645.
64. Tsuchiya S. The role of microRNA-210 in esophageal squamous cell carcinoma. Yakugaku Zasshi 2012, 132(9):1069-1073. [in Japanese].
65. Zhang M., Zhou S., Zhang L., Zhang J., Cai H., Zhu J., et al. miR-518b is down-regulated, and involved in cell proliferation and invasion by targeting Rap1b in esophageal squamous cell carcinoma. FEBS Lett 2012, 586(September (19)):3508-3521.
66. Wang K., Li J., Guo H., Xu X., Xiong G., Guan X., et al. MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis 2012, 33(November (11)):2147-2154.
67. Kurashige J., Watanabe M., Iwatsuki M., Kinoshita K., Saito S., Hiyoshi Y., et al. Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer 2012, 106(January (1)):182-188.
68. Yokobori T., Suzuki S., Tanaka N., Inose T., Sohda M., Sano A., et al. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci 2013, 104(January (1)):48-54.
69. Ni Y., Meng L., Wang L., Dong W., Shen H., Wang G., et al. MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma. Gene 2012, 517(December (2)):197-204.
70. Zhang T., Zhao D., Wang Q., Yu X., Cui Y., Guo L., et al. MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma. Mol Carcinog 2012, 52(February (8)):581-590.
71. Wu B.L., Xu L.Y., Du Z.P., Liao L.D., Zhang H.F., Huang Q., et al. MiRNA profile in esophageal squamous cell carcinoma: downregulation of miR-143 and miR-145. World J Gastroenterol 2011, 17(January (1)):79-88.
72. Lin R.J., Xiao D.W., Liao L.D., Chen T., Xie Z.F., Huang W.Z., et al. MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma. J Surg Oncol 2012, 105(February (2)):175-182.